Literature DB >> 15450983

ICU management of severe acute pancreatitis.

Alexander Wilmer1.   

Abstract

In intensive care medicine, severe acute pancreatitis (SAP) remains a very challenging disease with multiple complications and high mortality. The main pathophysiological mechanisms determining outcome are an uncontrolled systemic hyperinflammatory response early on and infection of pancreatic necrosis later on in the disease process. Despite a better understanding in recent years of the mechanisms and the mediators involved in the hyperinflammatory response, there is, as yet, no generally recognized specific treatment for this disease. Since early identification and aggressive treatment of associated organ dysfunction can have a major impact on outcome, early assessment of prognosis and severity is important. The evidence available indicates that patients with severe acute pancreatitis do not benefit from therapy with available antisecretory drugs or protease inhibitors. Supportive therapy, such as vigorous hydration, analgesia, correction of electrolyte and glycemia disorders, and pharmacological or mechanical support targeted at specific organs, is still the mainstay of therapy. In spite of meager evidence, prophylactic antibiotics with good penetration in pancreatic tissue are recommended in severe acute pancreatitis. Enteral nutrition via a nasojejunal tube has become the preferred route of feeding. Most patients with sterile necrosis do not benefit from surgical intervention. In patients with proven infection of pancreatic tissue, surgery is necessary. Percutaneous, radiological drainage techniques may eventually become an alternative form of drainage in selected patients.

Entities:  

Year:  2004        PMID: 15450983     DOI: 10.1016/j.ejim.2004.06.004

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  8 in total

1.  Minimally invasive percutaneous catheter drainage versus open laparotomy with temporary closure for treatment of abdominal compartment syndrome in patients with early-stage severe acute pancreatitis.

Authors:  Tao Peng; Li-Ming Dong; Xing Zhao; Jiong-Xin Xiong; Feng Zhou; Jing Tao; Jing Cui; Zhi-Yong Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-02-03

2.  Clinical outcomes in patients with ICU-related pancreatitis.

Authors:  Chia-Cheng Tseng; Wen-Feng Fang; Yu-Hsiu Chung; Yi-Hsi Wang; Ivor S Douglas; Meng-Chih Lin
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

3.  Early recognition of abdominal compartment syndrome in patients with acute pancreatitis.

Authors:  Zilvinas Dambrauskas; Audrius Parseliunas; Antanas Gulbinas; Juozas Pundzius; Giedrius Barauskas
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

4.  Acute renal failure in severe pancreatitis: A population-based study.

Authors:  Hung-Yuan Lin; Jiun-I Lai; Yi-Chun Lai; Po-Chou Lin; Shih-Chieh Chang; Gau-Jun Tang
Journal:  Ups J Med Sci       Date:  2011-01-20       Impact factor: 2.384

5.  Intra-abdominal hypertension in patients with severe acute pancreatitis.

Authors:  Jan J De Waele; Eric Hoste; Stijn I Blot; Johan Decruyenaere; Francis Colardyn
Journal:  Crit Care       Date:  2005-07-06       Impact factor: 9.097

6.  Intra-abdominal pressure in severe acute pancreatitis.

Authors:  Paivi Keskinen; Ari Leppaniemi; Ville Pettila; Anneli Piilonen; Esko Kemppainen; Marja Hynninen
Journal:  World J Emerg Surg       Date:  2007-01-17       Impact factor: 5.469

7.  Early intra-abdominal hypertension: A reliable bedside prognostic marker for severe acute pancreatitis.

Authors:  Kailash C Kurdia; Santhosh Irrinki; Arun V Chala; Ashish Bhalla; Rakesh Kochhar; Thakur D Yadav
Journal:  JGH Open       Date:  2020-08-04

8.  Pancreatic ductal deletion of S100A9 alleviates acute pancreatitis by targeting VNN1-mediated ROS release to inhibit NLRP3 activation.

Authors:  Hong Xiang; Fangyue Guo; Xufeng Tao; Qi Zhou; Shilin Xia; Dawei Deng; Lunxu Li; Dong Shang
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.